TargetBeta
NR3C2
nuclear receptor subfamily 3 group C member 2 · also MR, MLR · Nuclear receptor subfamily 3 group C
5 programs in company-led studies act on NR3C2, from 5 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| finerenonerule | Bayer | phase 4 | 254 running | – | ChEMBL |
| drospirenonerule | Estetra | phase 4 | 202 running | PGR | ChEMBL |
| Spironolactonerule | CMP Development | phase 4 | 81 running | – | ChEMBL |
| HRS-1780 | Jiangsu HengRui Medicine | phase 3 | 76 running | – | the company's pipeline |
| balcinrenonerule | AstraZeneca | phase 3 | 151 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Heart Failure, 3 programs
- Renal Insufficiency, Chronic, 3 programs
- Diabetes Mellitus, Type 2, 2 programs
- Bone Diseases, Metabolic, 1 program
- Cardiovascular Diseases, 1 program
- Contraception Behavior, 1 program
- Diabetic Nephropathies, 1 program
- Fasting, 1 program
- Fibrosis, 1 program
- Hemorrhage, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026HRS-1780 · Jiangsu HengRui Medicine · phase 3 · NCT07470983
- Apr 10, 2027finerenone · Bayer · phase 4 · NCT05196035
- Dec 2027drospirenone · Estetra · phase 4 · NCT05303636
- Jun 2028Spironolactone · CMP Development · phase 4 · NCT06021860
- Jul 1, 2030balcinrenone · AstraZeneca · phase 3 · NCT07624305
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.